Risk of Colorectal Cancer in Women With a Prior Diagnosis of Gynecologic Malignancy
Department of Medicine, Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. Journal of Clinical Gastroenterology
(Impact Factor: 3.5).
03/2007; 41(3):291-6. DOI: 10.1097/01.mcg.0000225587.85953.06
Earlier studies regarding the risk of colorectal cancer (CRC) in women with a prior diagnosis of gynecologic malignancies have revealed conflicting results. We sought to further clarify this association.
A retrospective cohort study was performed using the General Practice Research Database of the United Kingdom. Patients with a prior diagnosis of ovarian, uterine, or cervical cancers were compared with control patients without a prior gynecologic malignancy. The primary outcome was a diagnosis of CRC. Poisson regression analysis was used to assess the effects of potential confounders.
The study included 1995 ovarian, 1348 uterine, and 1101 cervical cancer patients and 7980, 5392, and 4404 matched control patients, respectively. The adjusted incidence rate ratio (IRR) of CRC among ovarian cancer patients was 2.90 [95% confidence intervals (CI) 1.45-5.82]. Five of 10 cases of CRC in ovarian cancer patients were diagnosed within 6 months of the cancer diagnosis with an adjusted IRR of 8.0 (95% CI 1.9-33.6). Excluding the initial 6 months of follow-up after the diagnosis of ovarian cancer, the adjusted IRR was 1.6 (95% CI 0.76-5.03). The adjusted IRR of CRC in patients with a prior diagnosis of uterine and cervical cancer was 0.79 (95% CI 0.24-2.61) and 1.50 (95% CI 0.43-5.21), respectively.
Women with a prior diagnosis of ovarian cancer are at an increased risk of CRC. The risk of CRC was not increased among patients with a prior history of uterine and cervical cancer.
Available from: Elizabeth Tracey
- ") and several studies have found an increased risk for colorectal and urinary bladder cancer after gynaecologic malignancies     . Lonn et al. estimated that 11% of solid cancers diagnosed more than 5 years after irradiation of uterine corpus cancer could be caused by radiotherapy . "
[Show abstract] [Hide abstract]
ABSTRACT: Uterine sarcomas (US) are rare malignancies with unclear aetiology. Studies on uterine sarcomas in the setting of second primary malignant tumours can provide clues to aetiology and identify side effects of different treatments.
A cohort of 8606 cases of US was extracted from the data from 13 cancer registries and followed for second primary cancers within the period 1943-2000. Standardized incidence ratios (SIRs) were calculated, and Poisson regression analyses were performed.
There were 499 cancer cases observed after a first diagnosis of US (SIR 1.26, 95%CI 1.16-1.38). SIRs were elevated for cancers of the mouth and pharynx (2.16, 95%CI 1.15-3.69), colorectum (1.60, 95%CI 1.28-1.98), lung (1.73, 95%CI 1.27-2.29), breast (1.25, 95%CI 1.05-1.49), urinary bladder (1.74, 95%CI 1.02-2.79), kidney (2.00, 95%CI 1. 24-3.06), thyroid gland (2.74, 95%CI 1.42-4.79), and soft tissue sarcoma (5.23, 95%CI 2.51-9.62). The risk of breast cancer increased along with increasing age of US diagnosis (p trend 0.040). The risk of kidney cancer increased along with decreasing age of US diagnosis (p trend 0.004) and short time since the US diagnosis (p trend 0.018).
Our study demonstrated increased risk of certain cancers following a diagnosis of US. The elevated risk for breast cancer may indicate shared hormonal aetiology, while the increased risk of colorectal and bladder cancers after US may be caused by radiation therapy of US. The clustering of smoking-related cancers after US is worth exploring in the future.
Gynecologic Oncology 04/2012; 126(1):30-5. DOI:10.1016/j.ygyno.2012.04.002 · 3.77 Impact Factor
Available from: sciencedirect.com
- "Personal history of other cancers ND A history of ovarian cancer but not of uterine or cervical cancer predisposes to CRC.  Family history of colon cancer One 1st-degree relative "
[Show abstract] [Hide abstract]
ABSTRACT: The risk of developing colorectal cancer (CRC) depends on both genetic factors and lifestyle-related factors. Chemoprevention's true contribution is dependent on lifetime CRC risk. There are clinical situations where chemoprevention for CRC is undoubtedly useful. There are other situations where the risk of CRC seems to be only moderately increased and in these situations, the true contribution of chemoprevention is questionable. A few specific studies assessing the effect of chemopreventive agents in these situations are available. In the present article, we will try to better define these particular situations and discuss the risk quantification and the expected chemoprevention contribution.
Best practice & research. Clinical gastroenterology 08/2011; 25(4-5):631-40. DOI:10.1016/j.bpg.2011.09.001 · 3.48 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Discovery of near-field generation by plasmons excited in thin AgO<sub>x</sub> layers made them important components in advanced optical technologies such as Super-RENS (H. Fuji et al, Jpn. J. Appl. Phys., vol. 39, p. 980, 2000) and the purely optical photonic transistor (J. Tominaga et al, Appl. Phys. Lett., vol. 78, p. 2417, 2001). In order to unravel the nanometer-scale mechanism of the silver nanoparticle formation upon photo-induced decomposition of the AgO<sub>x</sub> layer and its relationship with the plasmon generation efficiency, knowledge of the local structure of as-deposited AgO<sub>x</sub> layers and its modification upon thermal annealing and optical initialization is of utmost importance. A unique technique which allows determination of the local structure with atomic selectivity in both crystalline and amorphous states is X-ray absorption fine structure (XAFS) spectroscopy. In this paper, we present the results of the first such study applied to AgO<sub>x</sub> thin layers.
Optical Memory and Optical Data Storage Topical Meeting, 2002. International Symposium on; 02/2002
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.